Doc #4 — Pharmaceutical and Medical Supply Management

---

RECOMMENDED ACTIONS — SUMMARY

Phase 1: First 48 hours [IMMEDIATE]

1. Establish government operational authority over EBOS/ProPharma and CDC Pharmaceuticals wholesale warehouses.
2. Issue emergency dispensing restrictions to all community pharmacies via Medsafe.
3. Verify and protect cold chain infrastructure with backup power at all hospital pharmacy cold rooms.
4. Halt destruction or disposal of any expired medications pending shelf-life extension assessment.

Phase 1: Days 3–14 [URGENT]

5. Complete national pharmaceutical inventory at wholesale level using EBOS warehouse management systems.
6. Formally establish the National Pharmaceutical Management Authority within Te Whatu Ora.
7. Begin hospital and community pharmacy stock reporting and aggregation.
8. Establish national insulin registry — every vial tracked.
9. Confirm and distribute clinical rationing protocols (per Doc #116) to all prescribers and pharmacies.

Phase 1: Weeks 2–6 [HIGH PRIORITY]

10. Publish SLEP-based shelf-life extension list; distribute to all pharmacies and hospitals.
11. Inventory veterinary pharmaceutical stocks and establish veterinary-human review board.
12. Consolidate cold chain stocks into better-protected facilities.
13. Begin medical supply (non-pharmaceutical) inventory.
14. Establish regional buffer stocks at secondary centres.
15. Print and distribute pharmaceutical rationing guidance documents.

Phase 1: Months 2–6 [IMPORTANT]

16. Achieve full national pharmaceutical database — all sources aggregated and tracked.
17. Begin NZ-specific stability testing at University of Otago and University of Auckland.
18. Implement monthly consumption and depletion reporting for Category 1 and 2 drugs.
19. Execute inter-regional stock redistribution where needed.
20. Coordinate with Doc #119 to set local production priorities based on projected stock-outs.

Phase 1–2: Months 6–12 [ONGOING]

21. Review and adjust rationing protocols based on actual consumption data.
22. Assess and ensure regional allocation equity.
23. Plan for Phase 2 transitions as specific drug categories approach depletion.

---

---

1. THE SUPPLY CHAIN NZ HAS

1.1 Structure of the existing system

NZ’s pharmaceutical supply chain is concentrated, well-documented, and — critically — already centralised to a degree unusual among comparable countries:

Wholesale distribution: Two entities — ProPharma and CDC Pharmaceuticals, both subsidiaries of the ASX/NZX-listed EBOS Group — handle the majority of NZ’s pharmaceutical wholesale volume.¹ Their primary distribution warehouses are in Auckland and Christchurch. A smaller number of specialist wholesalers and direct-from-manufacturer supply arrangements exist, but EBOS subsidiaries dominate the pipeline. This concentration is an advantage for emergency management: the government needs to take operational control of one corporate group’s warehouses to control the majority of the wholesale supply.

Hospital pharmacies: NZ’s public hospital network — now operating under Te Whatu Ora / Health New Zealand — maintains pharmacy departments at every major hospital, with centralised procurement at the regional level.² Hospital pharmacies hold weeks to months of supply for their formulary items and have professional inventory management systems.

Community pharmacies: Approximately 1,000 community pharmacies operate across NZ, including chains (Green Cross Health’s Unichem and Life Pharmacy brands, with approximately 280+ outlets; the expanding Chemist Warehouse chain) and independents.³ Each pharmacy typically holds 1–4 weeks of supply for its high-turnover items. Chain pharmacies have centralised inventory systems; independents vary.

Aged residential care: NZ has approximately 650–700 aged residential care facilities housing roughly 35,000–40,000 residents.⁴ These facilities hold days to weeks of medication for their residents, typically supplied by a contracted community pharmacy.

Veterinary supply: Provet NZ (also an EBOS subsidiary) is the dominant veterinary pharmaceutical distributor, supplying approximately 600+ veterinary practices and agricultural retailers including PGG Wrightson and Farmlands stores.⁵ Veterinary stocks are geographically dispersed across rural NZ, reflecting the agricultural economy.

1.2 What NZ holds

Estimate: At any given time, the pharmaceutical supply pipeline holds approximately 2–6 months of supply for most commonly prescribed medications, distributed across wholesale warehouses (the largest concentration), hospital stores, and community pharmacies.⁶ This estimate is based on general pharmaceutical supply chain practices and industry norms for NZ’s market. Actual stock levels vary by drug — some sole-supply PHARMAC-contracted items may have deeper buffers; drugs with short shelf lives or cold-chain requirements (biologics, some insulins) typically have shallower stocks.

Fact: The exact aggregate stock levels are not publicly available. They are commercially sensitive data held by EBOS Group, individual hospital pharmacy departments, and pharmacy chains. The national inventory described in Section 4 is the only way to establish the actual figure.

Medical supplies beyond pharmaceuticals: NZ’s hospitals and clinics also hold finite stocks of:

• Surgical consumables (sutures, surgical gloves, drapes, wound dressings)
• Diagnostic consumables (blood test reagents, urine dipsticks, rapid test kits, culture media)
• Imaging consumables (contrast media, X-ray film for older systems — though digital imaging dominates)
• Anaesthetic supplies (endotracheal tubes, laryngeal masks, IV cannulae, syringes, needles)
• Personal protective equipment (gloves, masks, gowns)
• Dental materials (composites, amalgam, anaesthetic cartridges, impression materials)

These supplies are less well-tracked at national level than pharmaceuticals and receive less attention in emergency planning, but they are equally finite and in many cases equally critical.

1.3 NZ’s structural advantages

Two institutions give NZ capabilities that most countries lack for managing a pharmaceutical supply crisis:

PHARMAC (Pharmaceutical Management Agency) already makes centralised purchasing decisions for the publicly funded medicine supply — approximately 2,000 chemical entities in the national formulary.⁷ PHARMAC knows what has been purchased, in what quantities, from which suppliers, for which therapeutic purposes. PHARMAC’s therapeutic group managers have deep expertise in which drugs can substitute for which, and what the clinical trade-offs are. The public and the medical profession are accustomed to PHARMAC making allocation decisions. This institutional acceptance is directly transferable to a rationing framework. PHARMAC’s limitation is that its data covers publicly funded medicines only — private prescriptions, over-the-counter products, and veterinary pharmaceuticals are tracked separately or not at all.

Medsafe (New Zealand Medicines and Medical Devices Safety Authority), a business unit of the Ministry of Health, regulates medicines approvals and labelling requirements including expiry dates.⁸ Medsafe has the regulatory authority to issue emergency dispensing rules, revise expiry date requirements, and approve shelf-life extensions — all of which are needed in the first weeks.

1.4 The EBOS concentration — risk and opportunity

NZ’s dependence on a single corporate group for pharmaceutical wholesale distribution is, under normal conditions, a competition concern. Under emergency conditions, it is an operational advantage. The government needs to establish operational control of EBOS Group’s ProPharma and CDC facilities to manage the majority of the national pharmaceutical supply. This is a smaller, simpler task than it would be in a fragmented distribution market.

Risk: If an EBOS warehouse is physically damaged or destroyed (earthquake, fire — not expected in the baseline scenario but always possible), a disproportionate share of national stocks could be lost. Auckland is not in a high seismic zone relative to Wellington or Christchurch, but the volcanic field presents a low-probability, high-consequence risk, and the concentration of pharmaceutical stocks in one city is itself the vulnerability regardless of hazard type.⁹

Mitigation: Disperse a portion of wholesale stocks to secondary storage sites (see Section 5.3) within the first months. This is not urgent in the first days — the priority is inventory and control — but should be implemented once logistics allow.

---

2. MANAGEMENT FRAMEWORK

2.1 Institutional structure

The management framework operates at three levels:

National Pharmaceutical Management Authority (NPMA)

Established within the first two weeks, responsible for:

• Setting national rationing rules and triage categories (in coordination with the clinical framework in Doc #116)
• Managing wholesale stock allocation to regions and facilities
• Cold chain oversight
• Shelf-life extension policy
• Veterinary stock integration
• Consumption tracking and depletion projections
• Coordination with Doc #119 (Local Pharmaceutical Production) for production prioritisation

The NPMA should be housed within Te Whatu Ora / Health NZ, drawing on PHARMAC’s therapeutic expertise, Medsafe’s regulatory authority, and hospital pharmacy leadership. It is not a new bureaucracy — it is a coordinating function that directs existing institutions.

Assumption: This structure assumes functional government and institutional continuity. If government capacity is severely degraded, the framework simplifies to direct control of EBOS warehouses and emergency rationing rules communicated to pharmacies — the minimum viable version of the same strategy.

Regional distribution management

Te Whatu Ora’s regional structures (or their emergency management equivalents) manage distribution within their geographic areas:

• Allocating wholesale stock from central warehouses to hospitals and community pharmacies within the region
• Monitoring regional consumption rates and stock levels
• Managing regional cold chain infrastructure
• Handling inter-facility transfers (moving drugs from overstocked pharmacies to understocked ones within the region)

NZ’s existing District Health Board geography — four main regions based on the former Northern, Midland, Central, and Southern DHB clusters — provides a workable regional structure, though the specific boundaries matter less than having some regional layer between national and individual facility.¹⁰

Facility-level dispensing

Hospital pharmacies and community pharmacies continue dispensing under national rationing rules. Pharmacists make individual dispensing decisions within the framework — they decide whether a specific patient’s prescription falls within the rationing guidelines, advise prescribers on therapeutic alternatives, and manage their facility’s stock.

2.2 Interaction with Doc #1 (Stockpile Strategy)

Doc #1 classifies pharmaceuticals as Category A (wholesale requisition) and Category B (controlled distribution). This document implements both:

• Category A is the wholesale warehouse control described in Section 3 — the government takes operational authority over EBOS/ProPharma distribution centres and directs stock allocation.
• Category B is the controlled retail distribution described in Section 4 — pharmacies and hospitals continue dispensing under government rationing rules.

The distinction matters because the government is doing two different things: physically controlling wholesale inventory (Category A) and setting rules for retail dispensing (Category B). The first is a logistics operation; the second is a regulatory operation. Both are essential.

2.3 Interaction with Doc #116 (Pharmaceutical Rationing)

This document and Doc #116 are companion documents with distinct roles:

This document (Doc #4)	Doc #116
How to control the wholesale pipeline	Which drugs to prioritise
How to set up rationing logistics	How to triage patients
How to track inventory and consumption	Shelf-life extension science
How to manage cold chain infrastructure	Drug-by-drug stability analysis
How to integrate veterinary stocks	Dose optimisation protocols
How to communicate to pharmacy workforce	How to communicate to patients

The NPMA bridges both documents: it uses Doc #116’s clinical framework to make Doc #4’s allocation decisions. A drug that Doc #116 places in Triage Category 1 (life-sustaining) receives priority allocation through Doc #4’s distribution system.

---

3. WHOLESALE CONTROL

3.1 Securing the warehouses

Timeline: First 48 hours

This is the first pharmaceutical-specific action the government takes. Under the authority of the Civil Defence Emergency Management Act 2002 (or its successor, the Emergency Management Act 2023),¹¹ the government contacts EBOS Group’s senior management and establishes operational control of ProPharma and CDC Pharmaceuticals distribution facilities.

What this means in practice:

• EBOS warehouse staff continue their jobs. They know the systems, the inventory, the logistics. Replacing them with government personnel would be slower and less competent.
• The government embeds a liaison officer — ideally a pharmacist or pharmaceutical logistics specialist — at each major warehouse.
• No further distribution occurs without NPMA authorisation. The warehouse continues to fulfill orders, but the orders come from the government’s allocation framework rather than from commercial procurement.
• Existing inventory management systems provide the foundation for the national stock database. EBOS uses modern warehouse management software that tracks every product by SKU, batch number, expiry date, and location.¹²
• Physical security is provided if necessary, though this is unlikely to be contentious in the first days — these are commercial warehouses in industrial areas, not targets for panic buying.

Compensation: Documented at most recent wholesale cost. Settlement deferred per Doc #1, Section 2.2. EBOS Group shareholders and creditors hold a recorded claim against the government. This documentation matters for institutional legitimacy even if monetary compensation is not immediately meaningful.

3.2 Secondary wholesale and direct-supply channels

Not all pharmaceuticals flow through EBOS. Secondary channels include:

• Specialist hospital-only drugs supplied directly by pharmaceutical companies to hospital pharmacies (some oncology drugs, some biologics)
• Community pharmacy buying groups that purchase some products directly from manufacturers’ NZ subsidiaries
• Medical device and consumable distributors (Medtronic NZ, Fisher & Paykel Healthcare, Cardinal Health NZ) that supply hospitals with non-pharmaceutical medical supplies

Each of these channels must be identified and brought under NPMA coordination. This is less urgent than the EBOS warehouse control — these channels represent a smaller fraction of total supply and typically serve institutional customers who are already part of the health system — but should be completed within the first two weeks.

3.3 Stock that is NOT in warehouses

A significant fraction of the national pharmaceutical stock is already downstream — in hospital pharmacies, community pharmacies, and patients’ homes. The NPMA’s wholesale control captures only the pipeline stock that has not yet been distributed.

Hospital pharmacy stocks: Already within the government health system. Te Whatu Ora can direct reporting and control through existing management structures.

Community pharmacy stocks: In the hands of private businesses. The government does not requisition pharmacy shelf stock — it controls the supply of new stock from wholesale, which gives it effective control over what pharmacies can dispense. Pharmacies continue operating and selling what they have, but under rationing rules that limit dispensing quantities and prioritise clinical need. When a pharmacy needs to reorder, the order goes through the NPMA allocation system.

Patient-held stocks: Medicine in patients’ medicine cabinets is effectively unreachable and should remain so. Attempting to recall medications from individuals would be politically destructive, logistically impractical, and yield negligible returns. The exception: institutional settings (aged care facilities, prisons, boarding schools) where medication stores are centrally managed. These should report their stocks to the regional authority.

---

4. CONTROLLED DISTRIBUTION

4.1 How pharmacies operate under rationing

Community pharmacies continue dispensing prescriptions, but under modified rules issued by Medsafe under emergency authority:

Dispensing limits:

• Maximum 30-day supply per prescription (reduced from the current norm of up to 3 months for chronic medications)¹³
• No repeat dispensing without clinical review at each dispensing event
• Over-the-counter sales of key medicines restricted: paracetamol, ibuprofen, antihistamines, codeine-containing products limited to small quantities per customer per visit to prevent hoarding
• Controlled substances (opioids, benzodiazepines) already have restricted supply infrastructure — maintain and tighten

Prescription authority:

• All prescriptions remain clinically authorised — doctors, nurse practitioners, and authorised prescribers continue writing prescriptions within rationing guidelines
• Prescribers receive clinical guidelines from the NPMA (developed per Doc #116) that specify which drugs are available, at what doses, and for which indications under rationing
• Prescribers who believe a patient’s clinical need warrants an exception to rationing guidelines can escalate through the regional health authority

Stock reporting:

• Community pharmacies report weekly stock levels to the regional authority
• Chain pharmacies (Unichem/Life Pharmacy, Chemist Warehouse) can aggregate this through their existing centralised systems
• Independent pharmacies report through a standardised form — Medsafe can design and distribute this within days

Reorder authorisation:

• When a pharmacy’s stock of a rationed drug falls below a specified threshold, it submits a reorder request to the regional distribution authority
• The regional authority approves and fulfills the request from the NPMA-controlled wholesale stock
• This is the mechanism through which the government controls what is available at retail level without physically seizing pharmacy stock

4.2 Hospital pharmacy operations

Hospital pharmacies operate within a more structured environment and are easier to manage:

• Hospital formulary committees already control which drugs are stocked and prescribed within their institutions
• Hospital pharmacists are accustomed to managing drug shortages (which occur routinely in peacetime) and making substitution decisions
• Ward stock levels can be tightened — reducing ward stock means less waste from expiry and better central tracking
• Operating theatre and emergency department supplies are protected allocations — surgery and emergency care must continue

Key change: Hospitals are accustomed to ordering from wholesale distributors on a commercial basis. Under the emergency framework, orders go through the NPMA allocation system. The practical difference is small — the same drugs arrive at the same loading dock — but the authorisation pathway changes.

4.3 Aged residential care

NZ’s approximately 650–700 aged care facilities typically receive medications through a contracted community pharmacy. This arrangement continues under rationing — the supplying pharmacy applies rationing rules to its aged care clients as it does to its walk-in customers. Aged care facilities should report their medication stocks to the regional authority as part of the community pharmacy reporting framework.

Specific concern — polypharmacy and deprescribing: Elderly residents in aged care are among the most medication-dependent populations in NZ — polypharmacy (5+ medications per patient) is common.¹⁴ These are also the patients most likely to benefit from the deprescribing programme described in Doc #116, Section 5. Regional authorities should ensure that aged care facilities receive clinical support for medication review — either from their contracted pharmacist or from visiting GPs.

Ethical dimension: Deprescribing in aged care is an allocation decision with ethical weight. When total pharmaceutical supply is finite, continuing marginal medications for patients with short remaining life expectancy consumes supply that could extend treatment for patients with longer expected benefit. Doc #116, Section 9.2 addresses this tension directly. The key requirements for this document’s logistics framework are: (a) ensure clinical pharmacist access to aged care facilities for medication review within the first month, (b) ensure tapering — not abrupt withdrawal — for any medication being discontinued, and (c) communicate the rationale transparently to patients, families, and aged care staff. The goal is maximum total health benefit from finite supply, managed with dignity and honesty.

4.4 Veterinary distribution

Veterinary pharmaceutical distribution continues through existing channels — Provet NZ distributes to veterinary practices, which dispense to farmers and animal owners. Under the emergency framework:

• Provet NZ’s inventory is reported to the NPMA and included in the national stock database
• Veterinary drugs identified as usable for human medicine (see Section 6) are flagged for potential reallocation
• Veterinary practices continue dispensing for animal health purposes under their own rationing guidelines — NZ’s food production depends on animal health (Doc #74), and stripping veterinary stocks for human use while livestock epidemics go untreated would be counterproductive
• The allocation decision — how much veterinary stock to redirect to human use — is made by the NPMA based on clinical review and projected depletion rates for both human and veterinary needs

4.5 Centralised tracking

The rationing framework requires a national pharmaceutical database that tracks:

• Wholesale stock: What is in the warehouses, by drug, quantity, batch, and expiry date (including extended expiry per Doc #116)
• Allocation: What has been distributed to which region and facility
• Consumption: What has been dispensed to patients (aggregate, not individual patient data — though individual tracking exists for Category 1 drugs like insulin)
• Depletion projections: At current consumption rates, when does each drug run out?

Fact: NZ’s health system already has substantial pharmaceutical data infrastructure. PHARMAC’s purchasing data, EBOS’s warehouse management systems, hospital pharmacy inventory systems, and the NZ ePrescription Service (NZePS) provide much of this data.¹⁵ The challenge is aggregating it into a single operational view under emergency conditions — not building from scratch.

Assumption: This assumes that NZ’s IT infrastructure remains functional (grid continues, servers run, data networks operate — consistent with the baseline scenario). If IT infrastructure degrades, the system falls back to manual tracking: paper-based stock records at each warehouse and pharmacy, aggregated by phone or courier to regional authorities. This is vastly less efficient but was how pharmaceutical supply chains were managed for most of the 20th century.

---

5. COLD CHAIN MANAGEMENT

5.1 Why cold chain matters disproportionately

The medications that require cold chain storage (2–8°C for most; some require frozen storage) are the same ones with the shortest effective shelf lives and the fewest substitutes. This creates a compounding vulnerability: if the cold chain fails, the drugs lost are precisely those that are hardest to replace.

Cold chain-dependent pharmaceuticals in NZ include:

• Insulin (all types) — cold chain critical for unopened stock; in-use insulin tolerates room temperature for 28 days (varies by product)¹⁶
• Biologics and monoclonal antibodies — used in oncology, rheumatology, immunology. Expensive, small-volume, no substitutes for most indications
• Vaccines — NZ’s national immunisation programme stock, plus influenza and other vaccines in community pharmacy cold rooms
• Blood products and plasma-derived therapies — NZ Blood Service manages this supply separately from the pharmaceutical chain
• Some antibiotic injectables and IV fluids — though many of these are stable at room temperature for extended periods
• Some eye drops and ophthalmic preparations

5.2 NZ’s cold chain infrastructure

Under the baseline scenario (grid at 85%+ renewable, Doc #65), refrigeration continues to function. The cold chain risk is not systematic grid failure but localised or temporary interruption — a power outage, a generator failure, a compressor breakdown.

Current cold chain capacity:

• Hospital pharmacy cold rooms and dedicated pharmaceutical refrigerators at every hospital
• Community pharmacy refrigerators — every pharmacy has at least one dedicated pharmaceutical refrigerator
• EBOS/ProPharma warehouse cold storage — purpose-built pharmaceutical cold rooms at Auckland and Christchurch facilities
• NZ Blood Service cold storage facilities
• Commercial cold storage facilities (primarily in Auckland, Hamilton, Wellington, Christchurch)
• Household refrigerators — approximately 1.8 million households, each with at least one¹⁷

5.3 Cold chain protection protocol

Immediate actions (first 48 hours):

1. Identify all cold chain pharmaceutical stocks at wholesale and hospital level — this is part of the initial warehouse control process
2. Verify backup power at each cold chain storage location. Hospital pharmacies should already have generator backup; verify it covers the pharmaceutical cold room specifically
3. Ensure cold room temperature monitoring is functioning — most modern pharmaceutical cold rooms have continuous electronic monitoring with alarms. Where this does not exist, assign manual twice-daily temperature checks

Short-term actions (first month):

4. Consolidate cold chain stocks into fewer, better-protected locations. Multiple small pharmacy refrigerators are more vulnerable than one large, generator-backed hospital cold room. Transfer community pharmacy cold chain stocks to hospital pharmacies where practical — this trades geographic convenience for storage reliability
5. Establish a priority use protocol for cold chain stocks that experience temperature excursions: if a refrigerator fails and cold chain is broken, use those stocks first rather than discarding them. Insulin that has been at room temperature for less than 28 days is still usable. Many biologics tolerate brief temperature excursions.¹⁸
6. Assign backup generators specifically to cold chain facilities. If generator fuel must be rationed (Doc #53), pharmaceutical cold rooms receive priority allocation

Contingency: extended power outage

If a region loses grid power for an extended period (days to weeks — a contingency, not the baseline scenario):

• Insulated containers with ice packs can maintain 2–8°C for 24–48 hours, depending on ambient temperature and insulation quality
• NZ’s post-event ambient temperatures (cooled by nuclear winter) actually improve the feasibility of passive cold chain maintenance — if ambient temperature is 5–10°C, a well-insulated container maintains pharmaceutical cold chain range without active refrigeration
• As a last resort, underground storage (basements, cellars) in cool climate areas may provide temperatures close to cold chain requirements, particularly in the South Island during nuclear winter
• The NPMA should maintain a contingency plan for emergency redistribution of cold chain stocks from an affected region to one with functioning power

5.4 Insulin-specific cold chain

Insulin is the highest-priority cold chain pharmaceutical and deserves specific management:

• National insulin registry: Every vial, pen, and cartridge of insulin in NZ is tracked through the NPMA system. This is operationally demanding but justified by the criticality of the resource — approximately 20,000–25,000 Type 1 diabetes patients depend on insulin for survival.¹⁹
• Centralised cold storage: Unopened insulin stocks consolidated into the most reliable cold storage facilities — hospital pharmacy cold rooms with verified generator backup
• Distributed in small quantities: Insulin dispensed to patients in smaller quantities than peacetime norms (2–4 weeks rather than 3 months), reducing the volume at risk in uncontrolled home storage
• Cold chain break protocol: If insulin has been out of refrigeration, assess duration and temperature. Insulin at room temperature (below 25°C) retains potency for 28 days for most products; at higher temperatures, degradation accelerates. NZ’s post-event ambient temperatures (particularly during nuclear winter) may actually be within acceptable storage range in many locations during cooler months.

---

6. VETERINARY STOCK INTEGRATION

6.1 The veterinary pharmaceutical stockpile

NZ’s agricultural economy supports a substantial veterinary pharmaceutical supply chain that is rarely considered in human health emergency planning. Many veterinary drugs are chemically identical to human formulations — the same active pharmaceutical ingredients, often manufactured to the same Good Manufacturing Practice (GMP) standards, differing primarily in labelling, dose forms, and regulatory approval pathway.²⁰

NZ’s veterinary pharmaceutical stocks include drugs with direct human-use potential:

Drug category	Veterinary examples	Human equivalent	Notes
Penicillin antibiotics	Amoxicillin, ampicillin, procaine penicillin	Same APIs	Dose form may differ (some vet products are injectables designed for large-volume dosing)
Tetracycline antibiotics	Oxytetracycline, doxycycline	Same APIs	Widely used in livestock; large NZ stocks expected
Fluoroquinolone antibiotics	Enrofloxacin	Ciprofloxacin (metabolite of enrofloxacin in vivo)	Enrofloxacin is metabolised to ciprofloxacin
Anti-inflammatories	Meloxicam, phenylbutazone, flunixin	Meloxicam is the human-usable one	Phenylbutazone and flunixin are not approved for human use; meloxicam is
Anaesthetics	Ketamine, lidocaine, xylazine	Ketamine and lidocaine are human drugs	Xylazine is a veterinary sedative not normally used in humans
Antiparasitics	Ivermectin, fenbendazole, praziquantel	Same APIs (human formulations of ivermectin and praziquantel exist)	Dose forms differ significantly — animal drenches and pour-ons are not suitable for direct human administration
Electrolytes and fluids	Saline, Hartmann’s solution	Same formulations	Veterinary IV fluids may be manufactured to identical standards

Geographic distribution: Veterinary stocks are geographically dispersed across rural NZ — in veterinary practices, farm supply stores (PGG Wrightson, Farmlands), and on individual farms. This is both a challenge (harder to inventory than concentrated warehouse stocks) and a resilience advantage (not concentrated in a single vulnerable location).

6.2 Integration protocol

1. Inventory veterinary pharmaceutical stocks simultaneously with human pharmaceutical stocks. Provet NZ’s distribution data provides the wholesale layer; individual veterinary practices and farm supply retailers report their on-hand stock.

2. Establish a veterinary-human pharmaceutical review board — a joint panel of pharmacists, physicians, and veterinarians — within the NPMA. This board assesses each veterinary product for human usability: same active ingredient? Acceptable excipients? Appropriate dose form? The assessment is product-by-product, not blanket approval.

3. Maintain adequate veterinary supply. NZ’s food production depends on animal health. Livestock epidemics untreated because veterinary drugs were redirected to human use would produce a food production crisis that kills more people than the redirected drugs save. The NPMA must balance human and animal health needs, informed by veterinary and agricultural advice. Doc #74 (Pastoral Farming) provides context on livestock health requirements.

4. Apply shelf-life extension protocols equally. SLEP data applies to the chemical compound, not to the label. An amoxicillin capsule has the same degradation chemistry whether it is labelled for dogs or for humans. Veterinary stocks receive the same SLEP-based extension assessment as human stocks (Doc #116, Section 2).

5. Public communication. Some people will resist taking “animal medicine.” The communication must be scientific and matter-of-fact: the active ingredient is the same molecule regardless of the label. This is a regulatory distinction, not a chemical one. The veterinary-human review board’s clinical endorsement of specific products provides the credibility foundation.

6.3 What veterinary stocks do NOT provide

Veterinary pharmaceutical integration is a useful supplement, not a solution to the overall supply constraint. Limitations:

• Dose forms are often incompatible. Cattle drenches and pour-on formulations are not suitable for human oral administration — the concentration, vehicle, and excipients differ. Only products in compatible dose forms (tablets, capsules, injectable solutions, topical preparations with acceptable ingredients) are usable.
• Quantities may be modest relative to human need. NZ has approximately 5 million people and approximately 10 million cattle, 26 million sheep, and smaller numbers of other livestock.²¹ But animals do not take daily medications the way chronic disease patients do — veterinary pharmaceutical consumption is episodic and event-driven, so the in-country stock may be smaller relative to potential human need than the animal population numbers suggest.
• Some important human drugs have no veterinary equivalent. Insulin, most psychiatric medications, most cardiovascular drugs, and hormonal medications are not used in veterinary medicine (or are used in very small quantities). Veterinary integration does not address the most critical shortages.

---

7. MEDICAL SUPPLIES BEYOND PHARMACEUTICALS

7.1 Scope

Pharmaceuticals receive the most attention in supply management planning, but hospitals and clinics also depend on a range of non-pharmaceutical medical supplies that are equally imported and equally finite:

Surgical consumables: Sutures (absorbable and non-absorbable), surgical gloves (latex and nitrile), surgical drapes and gowns, wound dressings and bandages, wound closure strips, surgical staples, cautery tips, surgical blades.

Diagnostic consumables: Blood collection tubes (vacutainers), reagents for automated analysers (biochemistry, haematology, microbiology), urine dipsticks, rapid test kits, culture media, microscope slides and cover slips, staining reagents.

Anaesthetic consumables: Endotracheal tubes, laryngeal mask airways, IV cannulae, syringes, needles, giving sets (IV lines), three-way taps, arterial line kits.

Imaging consumables: Contrast media (iodinated contrast for CT; gadolinium for MRI), ultrasound gel. X-ray film is largely superseded by digital imaging but some facilities may still use it.

Personal protective equipment: Nitrile and latex examination gloves, surgical masks, N95/P2 respirators, eye protection, gowns.

Dental supplies: Composite and glass ionomer restorative materials, amalgam, dental impression materials, local anaesthetic cartridges, dental burs, endodontic files.

7.2 Management approach

Medical supplies are managed through the same framework as pharmaceuticals — wholesale control plus controlled institutional distribution — but with some differences:

• Procurement channels differ. Medical supplies come through medical device and consumable distributors (Cardinal Health NZ, Medtronic NZ, Fisher & Paykel Healthcare for respiratory equipment) rather than through EBOS’s pharmaceutical pipeline. These distributors must be brought under NPMA coordination alongside the pharmaceutical wholesalers.
• Usage tracking is less precise. Pharmaceuticals are tracked per-dose through prescribing and dispensing systems. Surgical consumables are tracked at the case level (which supplies were used in which procedure) but with less granularity. Inventory management for medical supplies will be coarser than for pharmaceuticals.
• Substitution and conservation pathways exist. Reusable surgical instruments replace some disposable equivalents. Autoclaving extends the use of some single-use items (with caveats about material degradation). Harakeke-based wound dressings may substitute for manufactured bandages in some applications (Doc #100), though harakeke fibre lacks the sterility, uniform absorbency, and antimicrobial coatings of commercial dressings — it functions primarily as a binding and covering material, not a clinical wound management product. These pathways should be explored but not assumed to close the supply gap fully.
• Fisher & Paykel Healthcare is a significant NZ asset — a major medical device manufacturer headquartered in Auckland that produces respiratory humidification systems, nasal high-flow therapy devices, and neonatal care equipment.²² While the company depends on imported components and materials, its NZ-based manufacturing expertise and facilities represent domestic capability that few countries possess. Its operational continuity should be a priority for the NPMA.

7.3 Rationing medical supplies

Hospital clinical leaders — surgeons, anaesthetists, emergency physicians, ward charge nurses — should develop facility-level protocols for conserving medical supplies:

• Reduce unnecessary procedures. Elective procedures that consume scarce supplies are deferred. What constitutes “elective” shifts under emergency conditions — a joint replacement that was elective in peacetime becomes lower-priority than it already was when surgical consumables are finite.
• Minimise waste in essential procedures. Surgical teams trained in resource-constrained environments (as in conflict surgery or humanitarian medicine) use fewer consumables per procedure. Sharing this expertise across NZ’s surgical workforce is a training priority.
• Reprocess where safe. Some nominally single-use items (certain surgical instruments, some diagnostic components) can be cleaned, sterilised, and reused. This is standard practice in many countries and was standard in NZ before the shift to disposables. Hospital sterilisation departments (CSSD — Central Sterile Supply Department) have the infrastructure. Medsafe should issue guidance on which items can be safely reprocessed.
• Diagnostic prioritisation. Laboratory reagents are consumed with every test. Routine screening tests should be curtailed; diagnostic testing reserved for clinical decision-making where the result will change management.

---

8. GEOGRAPHIC DISTRIBUTION CHALLENGES

8.1 NZ’s pharmaceutical geography

NZ’s pharmaceutical stock is concentrated where the population and warehouses are — primarily in Auckland and Christchurch. Regional and rural areas hold much less stock and are more vulnerable to supply disruption.

Auckland: Contains the largest EBOS/ProPharma warehouse, the highest density of community pharmacies and hospital pharmacies, and the largest patient population (~1.7 million people in the Auckland region).²³ Auckland is the centre of gravity for pharmaceutical supply.

Christchurch: Contains the second major EBOS distribution warehouse and serves the South Island. Christchurch has its own concentration risk — the city experienced major infrastructure damage in the 2010–2011 earthquakes, demonstrating that NZ’s urban infrastructure is not invulnerable.²⁴

Wellington, Hamilton, Dunedin, Tauranga: Secondary centres with hospital pharmacies and community pharmacy networks but no major wholesale warehouses. These cities depend on regular wholesale deliveries from Auckland or Christchurch.

Rural NZ: Small-town pharmacies and rural hospitals hold minimal stock — days to 1–2 weeks for most items. These facilities depend entirely on the wholesale delivery chain. If that chain is disrupted (fuel shortage, road closure, logistics failure), rural communities lose pharmaceutical access quickly.

8.2 Distribution under constrained transport

Post-event transport constraints (fuel rationing, reduced vehicle fleet) affect pharmaceutical distribution. The mitigation:

• Pharmaceutical deliveries receive fuel allocation priority. Doc #53’s fuel allocation tiers should place pharmaceutical distribution in the highest-priority category alongside food and medical services.
• Consolidate delivery runs. Instead of daily wholesale deliveries to individual pharmacies, shift to weekly or fortnightly bulk deliveries to regional hubs, from which local distribution occurs. This reduces fuel consumption per unit delivered.
• Buffer stocks at regional hubs. Hospital pharmacies in secondary centres (Wellington, Hamilton, Dunedin, Tauranga) should hold deeper buffer stocks than peacetime norms — 2–3 months rather than weeks — to provide resilience against delivery disruption.
• Coastal shipping. NZ’s port infrastructure enables pharmaceutical supply to be moved by coastal vessel between Auckland, Wellington, Christchurch (via Lyttelton), and Dunedin (via Port Chalmers) if road transport is constrained. Pharmaceutical freight is high-value, low-volume — ideal for constrained shipping capacity.
• Air transport. While fuel is available for aviation, time-critical pharmaceutical deliveries (emergency medications, blood products) can use air transport. This is a declining resource as aviation fuel depletes but available in Phase 1.

8.3 Equity between regions

Pharmaceutical rationing must be equitable between regions, not only between individuals. A system that maintains comfortable supply in Auckland while rural Southland runs out would be unjust and would undermine compliance nationally. The NPMA’s allocation framework should distribute stock proportionate to patient population, adjusted for regional disease burden and demographic factors (e.g., regions with older populations need more cardiovascular and diabetes medications; regions with higher Maori and Pacific populations have different disease profiles).²⁵

---

9. TRADITIONAL THERAPEUTICS AND EQUITABLE ACCESS

9.1 Rongoā Māori as a pharmaceutical supplement

Rongoā Māori — traditional Māori medicine using NZ-native plant species — is not a replacement for pharmaceutical supply but is a quantifiable supplement that reduces demand on finite imported stocks for a defined range of conditions. This matters at the margin: even a modest reduction in pharmaceutical demand for wound care, respiratory illness, and mild pain management — estimated at perhaps 2–5%, though no direct measurement exists for this scenario — extends the supply timeline for drugs that serve life-sustaining functions.²⁶

The relevant rongoā applications for a supply-constrained scenario are those with the clearest evidence base and widest availability. They are not treatments for Type 1 diabetes, sepsis, or cardiac arrhythmia — conditions where the pharmaceutical substitution gap is clinically unacceptable. They are treatments for the conditions where pharmaceuticals were already the secondary choice: minor wounds, dermatitis, respiratory symptoms, mild pain, and anxiety.²⁷

High-availability rongoā species with documented therapeutic applications:

Species	Te reo name	Application	Evidence basis	Geographic range
Leptospermum scoparium	Mānuka	Wound dressing (antimicrobial), honey-based wound management, oral/skin infections	Strong — mānuka honey is commercially produced and clinically validated; bark and leaf preparations have documented antimicrobial activity	Nationwide; abundant in scrub and regenerating bush
Kunzea ericoides	Kānuka	Wound care, respiratory steam inhalation	Good — closely related to mānuka; similar antimicrobial profile	Nationwide
Pseudowintera colorata	Horopito	Antifungal (polygodial compound), topical pain relief, dental pain	Good — polygodial is an active antifungal with published pharmacology	North and South Island bush
Corynocarpus laevigatus	Karaka	Bark used for skin conditions, swelling	Traditional; limited formal pharmacology	Coastal and lowland
Hebe spp.	Koromiko	Gastrointestinal illness, diarrhoea	Traditional; clinical validation limited but consistent with known astringent compounds	Nationwide; many cultivated forms
Phormium tenax	Harakeke	Wound dressings (leaf binding material), constipation, boils	Traditional; primarily mechanical wound management	Nationwide; cultivated at marae
Cordyline australis	Tī kōuka	Wound care, burns	Traditional	Nationwide

Assessment: Mānuka honey wound management is the highest-value rongoā application under supply constraints — clinically validated, immediately available (NZ produces approximately 10,000–20,000+ tonnes of mānuka honey annually pre-event, with substantial stockpiles), and directly substitutes for commercial wound dressings and topical antiseptics that are imported.²⁸ The NPMA should formalise mānuka honey as an approved medical-grade wound treatment within the first weeks, releasing pressure on manufactured antiseptic and wound care supply.

Horopito-derived antifungal preparations address a gap that matters: systemic antifungals (fluconazole, itraconazole) are imported and will deplete. Fungal infections — tinea, candidiasis, oral thrush — are not life-threatening but significantly burden healthcare capacity if untreated and spreading in a resource-constrained population.

Integration protocol: Tohunga rongoā (traditional Māori healing practitioners) are the appropriate assessors of rongoā application and preparation. They should be engaged by the NPMA’s medical supply team — not as cultural advisors in a secondary role but as clinical consultants for the subset of conditions where their knowledge is directly applicable. This is consistent with the engagement framework in Doc #160 (Heritage Skills Preservation), which recommends compensated practitioner engagement through iwi networks from Phase 1 Month 2 onward. The NPMA can begin identifying practitioners through existing rongoā networks (Te Kāhui Rongoā Trust, regional Māori health providers) within the first weeks.

Limitation that must be stated explicitly: Rongoā Māori does not address the critical pharmaceutical categories identified in Doc #116 — insulin, cardiovascular drugs (antihypertensives, anticoagulants), psychiatric medications, immunosuppressants, chemotherapy agents, and antibiotics for serious infections. For these categories, there is no traditional substitute that closes the performance gap. Planning that overstates rongoā’s scope would be dangerous. The honest claim is that it supplements care for a defined range of minor to moderate conditions, reducing pharmaceutical consumption at the margin.

Demand reduction through community care networks: Whānau-based care models — in which care for elderly, chronically ill, and mentally unwell people is distributed across family and community — reduce pharmaceutical demand by reducing polypharmacy, emergency presentations, and reliance on aged residential care.²⁹ Marae activated as civil defence centres (Doc #150) can serve as pharmaceutical distribution nodes and primary care access points, reducing transport demand on the distribution system (Section 8.2). The NPMA should coordinate with regional Māori health providers (approximately 12% of NZ primary care contacts³⁰) to ensure these providers are resourced and included in the distribution network.

Tohunga rongoā as primary care workforce: Tohunga rongoā are a real primary care resource for wound care, respiratory illness, gastrointestinal complaints, and mental health support — the same conditions where rongoā applications are strongest.³¹ Current health law does not prohibit rongoā practice. The NPMA should identify practitioners through Māori health providers, iwi health authorities, and Te Kāhui Rongoā Trust within the first month, include them in the regional healthcare workforce register with defined scope of practice, and provide basic supply access (wound dressings, clean water, sterilisation capacity). Their additional value as community health communicators — reducing delayed presentations and missed diagnoses in Māori communities — directly reduces pharmaceutical consumption.

9.2 Treaty of Waitangi obligations and equitable pharmaceutical access

Pharmaceutical rationing under a per-capita-only allocation model will systematically under-resource communities with higher chronic disease burdens. Māori and Pacific populations have significantly higher rates of Type 2 diabetes, cardiovascular disease, and chronic kidney disease than national averages — conditions that are among the highest pharmaceutical consumers.³² A rationing system that allocates drugs proportionate to population without adjusting for disease burden effectively discriminates against populations that have worse health profiles, often because of historical deprivation.

This is not only a Treaty of Waitangi concern, though it is that.³³ It is a practical public health concern: under-treating chronic disease in high-prevalence populations increases the rate of acute complications (diabetic ketoacidosis, stroke, renal failure), which consume vastly more healthcare resources than the ongoing medications they prevent. Under-allocation of preventive medications to high-need populations generates acute demand peaks that overwhelm hospital capacity and consume expensive, irreplaceable emergency medications.

The NPMA’s allocation framework must explicitly:

1. Adjust regional pharmaceutical allocations for disease burden — not distribute per capita uniformly. Regions with higher Māori and Pacific populations, which have systematically higher rates of cardiovascular disease, diabetes, and renal disease, receive proportionately more of the relevant drug classes (antihypertensives, antidiabetics, antiplatelets, dialysis-related medications).

2. Use iwi and hapū governance structures as distribution partners for reaching Māori communities, particularly in rural and remote areas where standard pharmacy networks have lower penetration. Iwi health authorities with existing patient rosters and delivery infrastructure are more efficient distributors than newly-built government channels.

3. Monitor pharmaceutical access rates by ethnicity throughout Phase 1. If Māori or Pacific communities are receiving proportionately less pharmaceutical access relative to disease burden, the NPMA has an obligation to correct this — and a practical incentive, since the consequences of under-treatment (acute hospitalisations, death) fall on the health system.

4. Include Māori health providers in the NPMA’s governance structure. This is recommended in Doc #150, Section 2 — the principle that Māori health institutions be included operationally. For pharmaceutical management specifically, this means including Te Whatu Ora’s Māori health directorate and major iwi health providers in the NPMA’s advisory and reporting structures from establishment.

The Treaty framing is functionally accurate: the Crown’s Treaty obligations to actively protect Māori health are legally operative constraints on how emergency powers are exercised.³⁴ An emergency pharmaceutical rationing system that demonstrably worsened Māori health outcomes relative to non-Māori, when equitable allocation was operationally achievable, would create post-event governance liabilities that complicate the recovery itself. The practical and principled arguments point in the same direction.

See Doc #150 (Treaty of Waitangi and Māori Governance) for the broader governance framework, and Doc #160 (Heritage Skills Preservation) for the integration methodology for traditional knowledge systems across all recovery domains.

---

10. IMPLEMENTATION TIMELINE

10.1 First 48 hours

Action	Responsible entity	Notes
Contact EBOS Group; establish government operational authority over ProPharma and CDC warehouses	NPMA (or predecessor emergency authority)	The single highest-leverage pharmaceutical action
Issue emergency dispensing restrictions to all pharmacies	Medsafe	30-day max supply, OTC restrictions, no uncontrolled hoarding
Verify cold chain backup power at hospital pharmacies	Te Whatu Ora	Identify any gaps immediately
Halt destruction of expired pharmaceuticals	Medsafe	No medication should be discarded until shelf-life extension assessment is complete

10.2 Days 3–14

Action	Responsible entity	Notes
Complete national pharmaceutical inventory (wholesale level)	NPMA using EBOS data	This is the most readily accessible and most valuable data — warehouse management systems already track it
Begin hospital pharmacy inventory aggregation	Te Whatu Ora	Each hospital reports its stocks to the regional authority
Begin community pharmacy stock reporting	Medsafe + regional authorities	Chain pharmacies report centrally; independents report via standardised form
Establish the NPMA formally	Te Whatu Ora / PHARMAC / Medsafe	Convene the authority; issue terms of reference
Confirm triage categories and rationing protocols (per Doc #116)	NPMA	Clinical rationing rules issued to all prescribers and pharmacies
Begin insulin registry	NPMA	Every vial tracked; Type 1 patients registered
Identify secondary wholesale and direct-supply channels	NPMA	Specialist hospital drugs, medical device distributors, buying groups
Engage Māori health providers and iwi health authorities as distribution partners	NPMA + Te Whatu Ora Māori health directorate	Per Doc #150 — include iwi health authorities in NPMA governance; confirm patient rosters and delivery capacity

10.3 Weeks 2–6

Action	Responsible entity	Notes
Publish SLEP-based shelf-life extension list (per Doc #116)	NPMA / Medsafe	National guidance: do not discard; assess and relabel
Begin veterinary stock inventory	NPMA + Provet NZ	Inventory veterinary warehouse and practice-level stocks
Establish veterinary-human pharmaceutical review board	NPMA	Joint panel assesses human usability product-by-product
Cold chain consolidation	Regional authorities	Transfer vulnerable cold chain stocks to better-protected facilities
Begin medical supply inventory	NPMA + medical device distributors	Non-pharmaceutical supplies: surgical, diagnostic, dental
Issue prescriber rationing guidelines	NPMA	Dose optimisation, therapeutic switching, deprescribing protocols (Doc #116)
Establish regional buffer stocks	Regional authorities	Build deeper buffers at secondary centres
Print and distribute rationing guidance documents	Doc #5 printing operation	Ensure every pharmacy and hospital has physical copies
Identify practising tohunga rongoā through iwi networks and Māori health providers; include in regional healthcare workforce register	NPMA + iwi health authorities	Per Section 9.1 — define clinical scope; provide supply access; activate as community triage and communication resource
Formalise mānuka honey as approved medical-grade wound treatment; issue clinical guidance	NPMA / Medsafe	Reduces demand on imported antiseptic and wound care supplies immediately
Begin disease burden-adjusted allocation modelling for pharmaceutical distribution	NPMA	Incorporate Māori and Pacific disease burden data into regional allocation formula; audit access rates by ethnicity

10.4 Months 2–6

Action	Responsible entity	Notes
Full national pharmaceutical database operational	NPMA	Wholesale + hospital + community pharmacy + veterinary stocks aggregated
Begin NZ-specific stability testing (if analytical capacity available)	Universities / Medsafe labs	Test actual NZ-held stock under actual conditions (Doc #116, Section 7.3)
Implement consumption tracking	NPMA	Monthly depletion reports for all triage Category 1 and 2 drugs
Stock redistribution between regions	NPMA	Move drugs from oversupplied to undersupplied regions
Assess medical supply reprocessing protocols	Hospital CSSD departments	Which single-use items can be safely reprocessed?
Coordinate with Doc #119 (Local Production)	NPMA	Provide production priority list based on projected stock-out dates

10.5 Months 6–12

Action	Responsible entity	Notes
Review and adjust rationing protocols	NPMA	Based on 6 months of consumption data; relax restrictions where stocks are confirmed adequate
Assess regional equity	NPMA	Are all regions receiving proportionate allocation?
Cold chain infrastructure review	Regional authorities	Any failures? Equipment degradation? Generator fuel allocation still adequate?
Expand stability testing programme	Universities / Medsafe	Broaden the range of drugs tested
Begin transition planning for Phase 2	NPMA	As stocks deplete for some drugs, what changes? Where are the approaching stock-outs?

---

11. CRITICAL UNCERTAINTIES

Uncertainty	Impact if wrong	Resolution method
Actual in-country pharmaceutical stock levels	Overestimated stock means earlier depletion than planned; underestimated stock means unnecessarily strict rationing	National inventory (Section 10.2) — the single highest-priority information task
EBOS Group cooperation	If EBOS management or staff resist government operational control, the warehouse takeover is slower and more disruptive	Pre-event relationship building with EBOS leadership; legal authority under emergency management legislation; retain and compensate existing staff
Cold chain reliability over multi-year timeframe	Refrigeration equipment failures destroy cold chain-dependent stocks — primarily insulin and biologics	Backup power, consolidation, monitoring, contingency plans (Section 5)
Medical supply stock levels	Non-pharmaceutical medical supplies are less well-tracked than drugs; actual stocks may surprise in either direction	Inventory through medical device distributors (Section 10.3)
Veterinary stock human usability	Some veterinary formulations may be unsuitable for human use due to excipients or dose forms	Product-by-product review board assessment (Section 6.2)
Transport capacity for distribution	Fuel rationing may constrain wholesale-to-pharmacy delivery capacity	Priority fuel allocation, delivery consolidation, coastal shipping contingency (Section 8.2)
IT system availability for tracking	If data networks degrade, centralised tracking becomes paper-based and much less efficient	Fallback to manual systems; maintain paper-based backup procedures
Community pharmacy compliance with rationing rules	If pharmacies under-report stock, overfill prescriptions, or operate outside rationing guidelines, the system leaks	Audit and compliance monitoring; visible enforcement for egregious violations; pharmacist professional ethics generally support compliance
Rural and remote supply continuity	Small-town pharmacies may run out before resupply arrives; remote communities may lose pharmaceutical access entirely	Regional buffer stocks; delivery prioritisation; community health worker dispensing authority for remote areas
Patient compliance and black market diversion	If patients stockpile or trade medications, the rationing system is undermined	Communication (Doc #2), visible fairness, accessible appeals (Doc #116, Section 9)

---

12. CROSS-REFERENCES

Document	Relationship
Doc #1 — National Emergency Stockpile Strategy	Parent framework. Pharmaceuticals are Category A (wholesale) and Category B (controlled distribution). This document implements both.
Doc #2 — Public Communication	Messaging framework for pharmaceutical rationing to patients and the public.
Doc #3 — Food Rationing and Distribution	Rationing framework that parallels pharmaceutical rationing.
Doc #8 — Skills and Asset Census	Must include pharmaceutical inventory, pharmacy workforce, medical workforce, and pharmaceutical analytical capacity.
Doc #33 — Tire Management	Transport constraints affecting pharmaceutical distribution mirror tire constraints.
Doc #65 — Hydro Maintenance and Grid Management	Grid reliability determines cold chain reliability. Cold chain failure destroys the most irreplaceable pharmaceutical stocks.
Doc #74 — Pastoral Farming	Veterinary pharmaceutical needs for livestock health must be balanced against human pharmaceutical needs.
Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension	Companion document. Provides the clinical rationing framework, triage categories, shelf-life extension science, dose optimisation protocols, and drug-by-drug analysis that this logistics framework implements.
Doc #119 — Local Pharmaceutical Production	Long-term supply solution. The NPMA provides production priority data to the Doc #119 programme based on projected stock-out timelines.
Doc #122 — Mental Health	Psychiatric medication rationing must be coordinated with mental health support. Medication withdrawal without psychosocial support is dangerous.
Doc #150 — Treaty of Waitangi and Māori Governance	Governance framework for including Māori institutions in the operational health response. Marae activation as civil defence centres; iwi health providers as distribution partners; Treaty obligations as constraints on emergency pharmaceutical allocation.
Doc #160 — Heritage Skills Preservation	Integration methodology for traditional knowledge systems, including rongoā Māori. Identification and engagement of tohunga rongoā through iwi networks; documentation of traditional knowledge under Māori-led protocols.

---

---

1. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. Specific stock levels are commercially sensitive and not publicly reported. Warehouse management systems track inventory by SKU, batch number, expiry date, and location.↩︎

2. Te Whatu Ora / Health New Zealand. https://www.tewhatuora.govt.nz/ — NZ’s national health service, established in 2022 by combining the 20 former District Health Boards into a single national organisation. Hospital pharmacies operate under Te Whatu Ora’s regional structures. The centralisation of health administration under Te Whatu Ora is, in principle, an advantage for emergency pharmaceutical coordination — though the organisation was still bedding in operationally at the time of writing.↩︎

3. Pharmacy Council of New Zealand. https://www.pharmacycouncil.org.nz/ — NZ has approximately 4,000+ registered pharmacists across approximately 1,000 community pharmacies and hospital pharmacy departments. Green Cross Health (NZX-listed) operates approximately 280+ pharmacies under the Unichem and Life Pharmacy brands. Chemist Warehouse has been expanding in the NZ market.↩︎

4. NZ aged residential care facility numbers from the Ministry of Health / Te Whatu Ora. Approximately 650–700 facilities nationally, housing roughly 35,000–40,000 residents. These figures are approximate and change as facilities open, close, or change capacity.↩︎

5. Provet NZ. https://www.provet.co.nz/ — An EBOS Group subsidiary and NZ’s primary veterinary pharmaceutical and supplies distributor. Supplies approximately 600+ veterinary practices and agricultural retailers nationwide. PGG Wrightson and Farmlands are the major agricultural supply retail chains holding veterinary products at the retail level.↩︎

6. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. Specific stock levels are commercially sensitive and not publicly reported. Warehouse management systems track inventory by SKU, batch number, expiry date, and location.↩︎

7. PHARMAC Annual Reports. https://www.pharmac.govt.nz/ — PHARMAC manages the Combined Pharmaceutical Budget (approximately NZ$1.2–1.4 billion per year), funding approximately 2,000 chemical entities. PHARMAC’s centralised procurement data and therapeutic switching expertise are directly applicable to emergency rationing.↩︎

8. Medsafe — New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/ — A business unit of the Ministry of Health / Manatū Hauora. Regulatory authority for medicine approval, labelling (including expiry dates), and post-market surveillance. Has authority to issue emergency dispensing rules and revise regulatory requirements under emergency conditions.↩︎

9. GNS Science seismic hazard assessments for NZ. Auckland has relatively low seismic hazard compared to Wellington and Christchurch (it is distant from major plate boundary faults) but sits on the Auckland Volcanic Field (approximately 53 known centres), which presents a volcanic rather than seismic risk. The concentration risk described here is primarily about logistics, not natural hazard — having the majority of national pharmaceutical stocks in one city is a vulnerability regardless of the local hazard profile.↩︎

10. Prior to the establishment of Te Whatu Ora in 2022, NZ’s health system was administered through 20 District Health Boards. The geographic footprint of these former DHBs — or the four regional clusters (Northern, Midland, Central, Southern) used for some planning purposes — provides a reasonable geographic framework for pharmaceutical distribution management.↩︎

11. Civil Defence Emergency Management Act 2002 and Emergency Management Act 2023. https://www.legislation.govt.nz/ — The legal framework for emergency requisition and resource management. Key provisions allow requisition of property for emergency purposes, with compensation. The 2023 Act substantially amended the earlier framework; the specific sections and their scope should be verified against current legislation.↩︎

12. EBOS Group Annual Reports and corporate disclosures. https://www.ebosgroup.com/ — EBOS Group is an ASX/NZX-listed company that owns ProPharma (NZ’s dominant pharmaceutical wholesaler) and CDC Pharmaceuticals. Together these entities handle the majority of NZ’s pharmaceutical wholesale distribution, with primary warehouses in Auckland and Christchurch. Specific stock levels are commercially sensitive and not publicly reported. Warehouse management systems track inventory by SKU, batch number, expiry date, and location.↩︎

13. PHARMAC and Medsafe dispensing guidelines. https://www.pharmac.govt.nz/ — Under normal NZ dispensing practice, community pharmacies may dispense up to 3 months’ supply of chronic medications in a single dispensing event, depending on the medicine and prescriber instructions. This norm varies by medication category and is subject to change.↩︎

14. Polypharmacy in NZ aged care: NZ health survey data and prescribing research indicate that polypharmacy (5+ medications) is common in older NZ adults, particularly in residential care settings. Boyd CM, et al. “Clinical Practice Guidelines and Quality of Care for Older Patients with Multiple Comorbid Diseases.” JAMA 294(6):716–724, 2005 — documents the general phenomenon. NZ-specific data from bpac NZ. https://bpac.org.nz/↩︎

15. NZ ePrescription Service (NZePS). https://www.health.govt.nz/ — NZ’s electronic prescribing system enables tracking of prescriptions dispensed through community pharmacies. PHARMAC’s pharmaceutical claims data provides national-level dispensing statistics. Hospital pharmacy systems (various vendors) track inpatient medication use. The data infrastructure exists but is not currently aggregated for emergency management purposes.↩︎

16. Insulin storage guidelines from manufacturer product information and Diabetes NZ. https://www.diabetes.org.nz/ — Unopened insulin vials should be stored at 2–8°C. Once in use, most insulin products tolerate room temperature (below 25–30°C) for 28 days, though some products have shorter room-temperature windows. Exposure to temperatures above 30°C or below 0°C damages insulin.↩︎

17. Stats NZ household data. https://www.stats.govt.nz/ — NZ has approximately 1.8–1.9 million households. Virtually all have at least one refrigerator. Household refrigerators are not suitable for pharmaceutical-grade cold chain management (temperature control is less precise, no monitoring or alarm systems) but provide last-resort cold storage capacity.↩︎

18. Insulin storage guidelines from manufacturer product information and Diabetes NZ. https://www.diabetes.org.nz/ — Unopened insulin vials should be stored at 2–8°C. Once in use, most insulin products tolerate room temperature (below 25–30°C) for 28 days, though some products have shorter room-temperature windows. Exposure to temperatures above 30°C or below 0°C damages insulin.↩︎

19. Diabetes NZ and Ministry of Health data. https://www.diabetes.org.nz/ — Approximately 20,000–25,000 NZers have Type 1 diabetes and are absolutely insulin-dependent. A further 40,000–60,000 Type 2 diabetes patients use insulin. See Doc #116, Section 5.4 for the insulin management strategy.↩︎

20. Many veterinary pharmaceuticals use the same active pharmaceutical ingredients as human formulations, manufactured under GMP standards. The regulatory distinction between human and veterinary drugs is primarily about labelling, dose forms, and approval pathway — not about the chemistry of the active ingredient. WHO Collaborating Centre for Drug Statistics Methodology — many ATC codes have identical veterinary equivalents.↩︎

21. Stats NZ agricultural statistics. https://www.stats.govt.nz/ — NZ’s livestock population includes approximately 10 million cattle (dairy and beef), 26 million sheep, and smaller numbers of deer, pigs, goats, and poultry. These numbers fluctuate seasonally and annually.↩︎

22. Fisher & Paykel Healthcare. https://www.fphcare.com/ — An NZX-listed company headquartered in Auckland, manufacturing respiratory humidification, nasal high-flow therapy, and neonatal care devices. One of NZ’s few significant medical device manufacturers. The company’s NZ manufacturing facilities and engineering expertise are nationally significant assets under emergency conditions, though they depend on imported components and materials for production.↩︎

23. Stats NZ population data. https://www.stats.govt.nz/ — Auckland region population approximately 1.7 million (roughly one-third of NZ’s total population of ~5.2 million). Auckland is the dominant pharmaceutical market and the location of the primary EBOS/ProPharma wholesale warehouse.↩︎

24. The 2010–2011 Canterbury earthquake sequence caused extensive infrastructure damage to Christchurch, including damage to hospital facilities and commercial buildings. While pharmaceutical warehouses were not uniquely affected, the event demonstrated that NZ’s second-largest city is vulnerable to seismic disruption. GNS Science reports on the Canterbury earthquake sequence.↩︎

25. Ministry of Health. “Tatau Kahukura: Maori Health Chart Book” and NZ Health Survey data. https://www.health.govt.nz/ — Disease burden varies significantly between regions and between ethnic groups. Maori and Pacific populations have higher rates of diabetes, cardiovascular disease, and renal disease. Regions with higher proportions of these populations require proportionately different pharmaceutical allocations. Equitable allocation requires adjusting for population health profile, not distributing per capita uniformly.↩︎

26. The 2–5% figure is an estimate, not a measured quantity. It is derived from the observation that wound care, respiratory illness, and mild pain management collectively represent a modest but non-trivial share of community pharmaceutical dispensing, and that rongoā applications with clinical evidence (particularly mānuka honey wound management) could partially substitute for imported products in these categories. No study has measured the pharmaceutical demand reduction from rongoā substitution in a supply-constrained scenario.↩︎

27. Riley J, et al. “Antimicrobial activity of mānuka honey in the treatment of chronic wounds.” International Wound Journal 9(4):440–448, 2012. Mavric E, et al. “Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand.” Molecular Nutrition & Food Research 52(4):483–489, 2008. Brooking SM, et al. “Antimicrobial properties of New Zealand honeys.” New Zealand Journal of Science 19:249–256, 1976. For horopito (polygodial): Kubo I, et al. “Polygodial, the antifungal component of Pseudowintera colorata.” Journal of Natural Products 47(6):1016–1020, 1984. For koromiko: Brooker SG, et al. New Zealand Medicinal Plants, Heinemann, Auckland, 1987 — the standard NZ ethnobotanical reference. Pharmacological validation of many rongoā species remains incomplete; claims in this table are graded by evidence quality where known. Te Kāhui Rongoā Trust (New Zealand Rongoā Practitioners’ Network): https://www.kahui-rongoa.org.nz/↩︎

28. NZ Mānuka Honey production statistics: Ministry for Primary Industries (MPI) / Māori Economic Development statistics. NZ exports approximately 10,000–20,000+ tonnes of mānuka honey annually (figures vary by year and definition of “mānuka”); domestic stockpiles and lower-grade honey not exported for medical use are significant. Commercial medical-grade mānuka honey dressings (Medihoney, Activon) are already produced in NZ and clinically validated for wound management. Under supply-constrained conditions, non-commercial-grade mānuka honey retains relevant antimicrobial activity, though standardisation is less precise. MPI bee industry statistics: https://www.mpi.govt.nz/↩︎

29. The relationship between social support, community cohesion, and reduced health service utilisation is documented in: Berkman LF, Glass T. “Social integration, social networks, social support, and health.” In: Berkman LF, Kawachi I (eds), Social Epidemiology. Oxford University Press, 2000. For Māori-specific hauora models in clinical settings: Durie MH. Whaiora: Maori Health Development (2nd ed.). Oxford University Press, Auckland, 1998. The empirical claim that hauora-based community responses reduce pharmaceutical demand is not directly proven in a post-catastrophe setting — it is an inference from general evidence on social support and health outcomes, acknowledged as an estimate rather than a measured quantity.↩︎

30. Te Whatu Ora / Health New Zealand Māori health provider data. Approximately 30+ Māori health providers operate nationally, with collectively approximately 300,000+ enrolled patients. The figure of “approximately 12% of NZ primary care contacts” is an estimate based on available Māori health sector analyses; the exact figure depends on definition of primary care contact and the year of data. Te ORA (the national Māori general practice body) and iwi health authorities provide additional primary care access. The key operational point — that Māori health providers already have patient rosters, staff, and relationships that make them effective distribution partners — is well-supported by sector evidence. Ministry of Health Māori health data: https://www.health.govt.nz/↩︎

31. The Tohunga Suppression Act 1907 (repealed by the Maori Welfare Act 1962) had prohibited tohunga practice. Current NZ health law — primarily the Health Practitioners Competence Assurance Act 2003 — regulates specified health professions but does not prohibit traditional healing practices that do not claim to treat regulated conditions or use regulated medicines. Te Whatu Ora funds rongoā Māori services through some Māori health provider contracts. Ministry of Health Rongoā Māori programme: https://www.health.govt.nz/↩︎

32. Ministry of Health. “Tatau Kahukura: Maori Health Chart Book” and NZ Health Survey data. https://www.health.govt.nz/ — Disease burden varies significantly between regions and between ethnic groups. Maori and Pacific populations have higher rates of diabetes, cardiovascular disease, and renal disease. Regions with higher proportions of these populations require proportionately different pharmaceutical allocations. Equitable allocation requires adjusting for population health profile, not distributing per capita uniformly.↩︎

33. Treaty of Waitangi obligations in health are established through: New Zealand Public Health and Disability Act 2000, s5 (Treaty principles apply to the health system); New Zealand Māori Council v Attorney-General [1987] 1 NZLR 641 (Court of Appeal) — established the principles of active protection, partnership, and participation as Treaty obligations. For health specifically: Came H, et al. “Upholding Te Tiriti, ending institutional racism and Crown inaction on health equity.” New Zealand Medical Journal 133(1508):2020. The operational implication is that emergency powers exercised under the Civil Defence Emergency Management Act or Emergency Management Act do not extinguish Treaty obligations — these continue to apply to how emergency authority is exercised.↩︎

34. Treaty of Waitangi obligations in health are established through: New Zealand Public Health and Disability Act 2000, s5 (Treaty principles apply to the health system); New Zealand Māori Council v Attorney-General [1987] 1 NZLR 641 (Court of Appeal) — established the principles of active protection, partnership, and participation as Treaty obligations. For health specifically: Came H, et al. “Upholding Te Tiriti, ending institutional racism and Crown inaction on health equity.” New Zealand Medical Journal 133(1508):2020. The operational implication is that emergency powers exercised under the Civil Defence Emergency Management Act or Emergency Management Act do not extinguish Treaty obligations — these continue to apply to how emergency authority is exercised.↩︎